Episode
399: Hair-raising trial results, and Servier’s M&A wishlist
- Podcast
- The Readout Loud
- Published
- Apr 30, 2026
- Duration seconds
- 2486
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-readout-loud-1134305/episodes/399-hair-raising-trial-results-and-servier-s-m-a-wishlist/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-readout-loud-1134305/399-hair-raising-trial-results-and-servier-s-m-a-wishlist.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Why are investors excited about hair loss drugs? Will artificial intelligence make clinical trials run more smoothly? And how does a nonprofit pharma company compete in the M&A arena? We get into all that and more on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast. Veradermics CEO Reid Waldman joined us to discuss his company’s data, and why hair loss is such a trendy topic in biotech. Then, Servier Pharmaceuticals CEO David Lee joined us to discuss the company’s acquisition of Day One Biopharmaceuticals.